EXOZYMES INC. Increase (Decrease) in Accounts Receivable
EXOZYMES INC. (EXOZ) reported Increase (Decrease) in Accounts Receivable of -$316.10 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- EXOZYMES INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$101.61K.
- EXOZYMES INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$214.50K.
- EXOZYMES INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $214.72K, a 17.13% increase year-over-year.
- EXOZYMES INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $45.24K.
- EXOZYMES INC. increase (decrease) in accounts receivable for fiscal 2025 was -$219.92K.
- EXOZYMES INC. increase (decrease) in accounts receivable for fiscal 2024 was -$145.04K, a 299.26% decline from fiscal 2023.
- EXOZYMES INC. increase (decrease) in accounts receivable for fiscal 2023 was $72.79K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$101.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$316.10K 10-Q · filed 2026-08-13 | -$101.39K derived: sum of 3 quarters · filed 2026-08-13 | -$56.15K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$214.50K 10-Q · filed 2026-05-14 | $220.00 derived: sum of 2 quarters · filed 2026-05-14 | $45.46K derived: sum of 3 quarters · filed 2026-05-14 | -$292.30K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $214.72K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $259.95K derived: sum of 2 quarters · filed 2026-03-30 | -$77.80K derived: sum of 3 quarters · filed 2026-08-13 | -$219.92K 10-K · filed 2026-03-30 |
| 2025-09-30 | $45.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$292.52K derived: sum of 2 quarters · filed 2026-08-13 | -$434.64K 10-Q · filed 2025-11-13 | -$251.32K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$337.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$479.88K 10-Q · filed 2026-08-13 | -$296.56K derived: sum of 3 quarters · filed 2026-08-13 | -$889.76K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$142.12K 10-Q · filed 2026-05-14 | $41.20K derived: sum of 2 quarters · filed 2026-05-14 | -$552.01K derived: sum of 3 quarters · filed 2026-05-14 | -$516.45K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $183.32K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$409.89K derived: sum of 2 quarters · filed 2026-03-30 | -$374.33K derived: sum of 3 quarters · filed 2026-03-30 | -$145.04K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$593.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$557.65K derived: sum of 2 quarters · filed 2025-11-13 | -$328.36K 10-Q · filed 2025-11-13 | -$122.49K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $35.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $264.85K 10-Q · filed 2025-08-12 | $470.72K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $229.29K 10-Q · filed 2025-05-12 | $435.16K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $205.87K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $72.79K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$133.08K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |